Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-08-14 Earnings Release
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the quarter ended June 30, 2025. It includes summary financial data such as revenue and profit figures for Q1 2025 compared to Q1 2024, along with commentary from company executives and key milestones achieved. The document is dated August 14, 2025, and is addressed to stock exchanges, indicating it is an official earnings announcement. The content focuses on quarterly financial performance highlights rather than a full detailed financial report or annual report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. The document length is about 5438 characters, which is consistent with a press release rather than a full interim report.
2025-08-14 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the quarter ended June 30, 2025. It includes summary financial performance data for Q1 2025-26, such as revenue and profit figures, and discusses key milestones and recognitions. The document is dated August 14, 2025, and is addressed to stock exchanges, indicating it is an official earnings announcement. The content is consistent with an Earnings Release (ER) as it provides initial quarterly financial results highlights without the full detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR). The document length is about 5438 characters, which is typical for an earnings release. Therefore, the appropriate classification is Earnings Release (ER).
2025-08-14 English
Please find the enclosed Financial Results for the quarter ended June 30, 2025.
Regulatory Filings
2025-08-14 English
Outcome of Board Meeting
Regulatory Filings
2025-08-14 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It mentions the enclosure of a certificate issued by the Registrar and Transfer Agents confirming compliance with a specific regulation. The document is short (1423 characters) and primarily serves as a submission or attestation of compliance rather than containing financial data or detailed report content. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a report publication announcement since it does not mention the publication or availability of a report. The document is best classified as a Regulatory Filing (RNS) because it is a compliance certificate submission to the stock exchanges, which fits the description of general regulatory announcements and compliance documents.
2025-08-12 English
Please find the enclosed intimation of the Company as per the captioned subject for reference.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) containing a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It is signed by the Company Secretary and encloses a certificate from the Registrar and Transfer Agents confirming compliance. The document is short (1423 characters) and primarily serves as a compliance certificate submission rather than a financial report or detailed filing. It does not contain financial data, management discussion, or report content. It is a regulatory compliance filing and certification. Therefore, it fits best under Regulatory Filings (RNS).
2025-08-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.